Caverion and Orion have signed an agreement on the technical maintenance of and managed services for Orion’s properties in Espoo, Turku, Salo and Kuopio. The total floor area of the properties covered by the four-year agreement is approximately 195,000 square metres. The value of the agreement is not disclosed.
Caverion is responsible for the technical maintenance of all building systems in Orion’s aforementioned properties, most of which are pharmaceutical plants, as well as for all managed services in relation to these. The building systems cover the heating and sanitation, ventilation and air-conditioning, cooling, electricity, information and communication technology, security and safety as well as automation systems. The agreement continues the ongoing cooperation between the two companies.
“We wanted to take our cooperation onto a new level and, since Caverion accepted the challenge, we were able to agree on simpler and more efficient processes, as well as on objectives for these. It is important that we implement these changes in the coming months,” says Juha Paasi, Orion’s EHS and property manager.
“Operating in the pharmaceutical segment is a challenge because of the strict requirements in the industry. We have a lot of knowledge of the industrial operating environment and our services help our clients focus on their respective core businesses,” says Jarno Hacklin, Executive Vice President & CEO at Caverion Finland.
Orion is a globally operating Finnish developer of pharmaceuticals and diagnostic tests. Orion belongs to Caverion’s industrial client segment.
For further information, please contact:
Kirsi Hemmilä, Communications Manager, Caverion Finland, tel. +358 50 390 0941, firstname.lastname@example.org
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.